Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer - LARVOL DELTA

Integrating spatial phytochemistry and metabolomics reveals the spatial chemical organization of Gymnadenia conopsea and its pharmacological effects in kidney-yang deficiency syndrome. (PubMed, J Ethnopharmacol) - "The present study provides experimental evidence supporting the traditional use of G. conopsea in kidney-yang deficiency syndrome. The therapeutic effects of G. conopsea are associated with the regulation of renal metabolic homeostasis, particularly energy metabolism and lipid metabolic pathways. By integrating spatial phytochemistry and spatial metabolomics, this study provides new insights into the spatial chemical organization and pharmacological actions of traditional medicinal plants and supports the rational utilization of G. conopsea resources."

Journal • Fatigue • Metabolic Disorders

HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study (clinicaltrials.gov) - P=N/A | N=180 | Completed | Sponsor: Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo | Recruiting ➔ Completed | Trial completion date: Feb 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jul 2026

Trial completion • Trial completion date • Trial primary completion date • Critical care • Infectious Disease • Pneumonia • Respiratory Diseases

Treatment of canine otitis externa: a randomized, double-blinded, clinical field study comparing the hydrocortisone aceponate monotherapy to a multi-agent reference product. (PubMed, Front Vet Sci) - "This multicentric, masked, randomized, clinical field trial in Japan evaluated the efficacy and safety of a hydrocortisone aceponate (HCA) spray solution (Cortotic™, Virbac, France) compared to a terbinafine/florfenicol/betamethasone acetate ear gel (Osurnia™, Bussan Animal Health CO Ltd, Japan) in 200 dogs with ECOE (OTIS3 ≥ 5). The use of Cortotic™, a corticosteroid-monotherapy, can offer an effective strategy for managing ECOE while avoiding unnecessary antibiotic exposure. This study supports Cortotic™ as a first-line therapeutic option for otitis externa in dogs."

Clinical • Journal • Monotherapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Otorhinolaryngology

A case of infusion reaction occurring during the second administration of sacituzumab govitecan. (JBCS 2026) - "Due to the presence of skin and respiratory symptoms, Polaramine and Solu-Cortef were administered on suspicion of an allergy. As there was no recurrence of symptoms and the patient's oxygen needs had subsided, the patient was discharged the following day. There is a possibility of another infusion reaction in the future, and administration of trastuzumab deruxtecan is being considered."

Clinical • Atrial Fibrillation • Breast Cancer • Congestive Heart Failure • Cough • Heart Failure • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Immunology • Pruritus • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Triple Negative Breast Cancer • HER-2

Usage of pembrolizumab and other preoperative/postoperative treatments at our hospital for ER-negative and HER2-negative high-risk recurrent breast cancer. (JBCS 2026) - "The regimen consisted of pembrolizumab 200mg Q3W, paclitaxel (PTX), and carboplatin (CBDCA) QW (80/AUC1.5) for 12 cycles, and pembrolizumab, epirubicin (Epi), and cyclophosphamide (CPA) (90/600) Q3W for 4 cycles...Treatment was started with an intravenous infusion of Solu-Cortef 200 mg, symptoms improved, and the dosage was gradually reduced while monitoring Na and Cl levels...Whether or not the dosage was reduced, or whether or not the treatment was completed, was not related to the treatment effect. It is necessary to keep irAEs in mind and conduct regular examinations and interviews."

Clinical • Breast Cancer • Endocrine Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Nephrology • Neutropenia • Oncology • Renal Disease • Solid Tumor • ER • HER-2

Pituitary Apoplexy Presenting as Refractory Hyponatremia (ENDO 2026) - "The patient was discharged on levothyroxine and a hydrocortisone taper. Pituitary apoplexy is a medical emergency requiring prompt recognition and initiation of hormone replacement therapy. Secondary adrenal failure may cause hyponatremia that is refractory to standard therapy thus mandating its consideration in this setting."

Cardiovascular • CNS Disorders • Endocrine Disorders • Growth Hormone Deficiency • Heart Failure • Hematological Disorders • Renal Disease

Discovery of novel 20S-protopanaxadiol derivatives in alleviating sepsis-associated liver injury by modulating p65/p50 activity. (PubMed, Eur J Med Chem) - "Remarkably, 9a alleviated SALI in a concentration-dependent manner, demonstrating superior efficacy to the glucocorticoid drug hydrocortisone sodium succinate...Molecular docking and cellular thermal shift assay (CETSA) confirmed that 9a bound to the p50 subunit, impairing the DNA-binding capacity of the p65-p50 heterodimer and consequently exerting anti-inflammatory activity. This study provides detailed SAR insights into 20S-PPD derivatives for anti-inflammatory drug development and offers new perspectives on their mechanism of action in mitigating SALI."

Journal • Hepatology • Infectious Disease • Inflammation • Liver Failure • Septic Shock

AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - P3 | N=5949 | Completed | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2026 ➔ Mar 2026 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • ETV6 • KMT2A • RUNX1

UniCort: Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Semmelweis University | Trial primary completion date: Sep 2025 ➔ Sep 2027

Trial primary completion date • CNS Disorders • Hypotension

Pituitary apoplexy presenting as refractory hyponatremia. (PubMed, JCEM Case Rep) - "The patient was discharged on levothyroxine and a hydrocortisone taper. Pituitary apoplexy is a medical emergency requiring prompt recognition and initiation of hormone replacement therapy. Secondary adrenal failure may cause hyponatremia that is refractory to standard therapy, thus mandating its consideration in this setting."

Journal • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Endocrine Disorders • Growth Hormone Deficiency • Heart Failure • Hematological Disorders • Nephrology • Pain • Renal Disease

Impact of shelf-life on the pharmaceutical equivalence assessment of a hydrocortisone semisolid W/O emulsion: Evaluation of rheological, structural, and release properties. (PubMed, Eur J Pharm Sci) - "Overall, the findings indicate that EMA's equivalence criteria with extended limits better reflect the natural variability of dispersed systems, although limits may need to be further broadened for some topical products. The results warrant further research to clarify the role of rheology in topical bioequivalence assessment."

Journal

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Children's Oncology Group | Trial completion date: Jun 2026 ➔ Mar 2028 | Trial primary completion date: Jun 2026 ➔ Mar 2028

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Myelodysplastic Syndrome • Oncology • NF1 • PTPN11

Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial. (PubMed, Lancet Respir Med) - P3 | "We have provided a publicly available three-biomarker framework to determine the extent of host response dysregulation with potential value for precision-guided immunomodulatory therapy."

Biomarker • Clinical • Journal • Critical care • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • IL6

Pharmacodynamic evaluation and mechanism study of cord blood nucleated cell extract in the treatment of rheumatoid arthritis. (PubMed, Clin Rheumatol) - "CBNCE modulates the Th17/Treg balance by decreasing the Th17 cells, suppressing the secretion of IL-1, IL-6, IL-8, and IL-17, enhancing the secretion of IL-4 and IL-10, and further inhibiting the expression of MMP-3 protein, thereby increasing the level of Aggrecan and Collagen type I. Ultimately, CBNCE alleviates RA. Key Points • Our study was the first to explore the effect and mechanism of cord blood nucleated cell extract in the treatment of rheumatoid arthritis. • This study offers a theoretical foundation and introduces a novel concept for utilizing cord blood in the treatment of rheumatoid arthritis."

Journal • PK/PD data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • ACAN • CXCL8 • IL10 • IL17A • IL4 • IL6 • MMP3

Enzymatic Synergy-Driven Biotransformation Generates a Postbiotic-Rich Functional Matrix That Reprograms Gut Microbiota Metabolic Pathways Under Stress Conditions. (PubMed, Int J Mol Sci) - "Untargeted metabolomics and deep shotgun metagenomic sequencing were integrated with a hydrocortisone-induced murine metabolic stress model to quantify substrate remodeling, host neuroendocrine/behavioral outcomes, and microbiome functional reprogramming...Enzymatic synergy-driven biotransformation yields a postbiotic-rich functional matrix that is associated with a selective remodeling of gut microbiome metabolic potential under stress and concomitant improvement in host physiological resilience. This study underscores microbial functional remodeling as a critical mechanistic interface linking fermentation-modified substrates to host physiological recovery, providing a molecular framework for the development of targeted postbiotic interventions."

Journal • Metabolic Disorders

DFCI 21-757: Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Andrew E. Place, MD | Active, not recruiting ➔ Recruiting | N=13 ➔ 30 | Trial completion date: Jul 2028 ➔ Jul 2030 | Trial primary completion date: Jul 2026 ➔ Jul 2028

Enrollment change • Enrollment open • Pan tumor • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology • ABL1 • BCL2 • BCR • FLT3 • IKZF1 • KMT2A

Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections (IMPACT) (clinicaltrialsregister.eu) - P4 | N=300 | Sponsor: Copenhagen University Hospital

New P4 trial • Infectious Disease

Pharmacological therapy for preventing esophageal stricture after endoscopic submucosal dissection: a systematic review and network meta-analysis. (PubMed, Int J Surg) - "In patients undergoing ESD, oral hydrocortisone sodium succinate combined with aluminum phosphate gel was the most effective intervention for reducing the incidence of postoperative esophageal stricture. The combination of PGA sheet plus fibrin glue was most effective in minimizing the number of EBD sessions required."

Journal • Retrospective data • Esophageal Cancer • Oncology

HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study (clinicaltrials.gov) - P=N/A | N=180 | Recruiting | Sponsor: Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo | Trial completion date: Jul 2024 ➔ Feb 2027 | Trial primary completion date: Apr 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Critical care • Infectious Disease • Pneumonia • Respiratory Diseases

AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - P3 | N=5949 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • ETV6 • KMT2A • RUNX1

Infusion-Related Reactions (IRR) and Management in Patients With Red Blood Cell (RBC) Transfusion-Dependent (TD) Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Imetelstat From the IMerge Phase 3 Trial (JADPRO 2025) - P2/3 | "Background/Significance • Myelodysplastic syndromes (MDS) are hematologic malignancies marked by ineffective hematopoiesis, cytopenias, and an elevated risk of progression to acute myeloid leukemia1 •Imetelstat is a first-in-class, direct, and competitive inhibitor of telomerase enzymatic activity, approved in the United States (US) for the treatment of adult patients with low- to intermediate-1-risk MDS with transfusion- dependent (TD) anemia requiring ≥4 red blood cell (RBC) units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)2 -Imetelstat is administered as an intravenous (IV) infusion over 2 hours every 4 weeks • Approval was based on the pivotal Phase 3 IMerge trial (NCT02598661), a multinational, randomized, double-blind, Phase 2/3 trial of imetelstat versus placebo in patients with RBC-TD, ESA-relapsed, refractory, or ineligible, and non-del(5q) lower-risk MDS Results showed..."

Clinical • P3 data • Acute Myelogenous Leukemia • Anemia • Dermatology • Hematological Malignancies • Immunology • Leukemia • Musculoskeletal Pain • Myelodysplastic Syndrome • Neutropenia • Pruritus • Thrombocytopenia • Urticaria

Radiation recall reactions triggered by COVID-19 infection in a patient with buccal cancer; A clinical report and review of the literature. (PubMed, IDCases) - "An RRR was diagnosed, and she was admitted for treatment with intravenous sulbactam/ampicillin and intravenous hydrocortisone sodium succinate. Her subsequent course has been uneventful, with no flareup of the RRR. This case is presented along with a review of relevant literature."

Journal • Dermatology • Infectious Disease • Novel Coronavirus Disease • Oncology • Otorhinolaryngology • Respiratory Diseases • CRP

AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - P3 | N=847 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD2 • CD20 • CD22 • CD34 • CD5 • CD7 • CD8 • MPO

Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov) - P1 | N=13 | Active, not recruiting | Sponsor: Andrew E. Place, MD | Recruiting ➔ Active, not recruiting | N=92 ➔ 13

Enrollment change • Enrollment closed • Pan tumor • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology • ABL1 • BCL2 • BCR • FLT3 • IKZF1 • KMT2A

Hormonal Mechanisms of Sleep Restriction - Axis Study (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Peter y. Liu | Trial completion date: Mar 2025 ➔ Jun 2026

Trial completion date